齐鲁晚报.齐鲁壹点姜曼 大幅提高生育医疗费待遇。职工住院分娩报销比例提高至100%，实现政策范围内个人"无自付"；居民住院分娩支付限额提高至3000元。"十四五"期间， 为13.53万人次参保职工和19.5万人次参保居民分别减轻生育医疗费负担5.44亿元、3.97亿元。 将辅助生殖纳入保障范围。辅助生殖通俗讲就是试管婴儿，自2024年4月1日起，治疗性辅助生殖类医疗服务项目可按规定报销。政策实施以来，惠及4.75 万人次、医保基金支出3064.32万元。 实现省内异地生育直接结算。自2025年7月起，参保职工在省内异地生育住院无需备案，惠及该市参保职工162人、减轻费用负担97.39万元。市外参保人 生育可在该市29家定点医疗机构直接联网结算。 推行生育津贴"即申即享"。医保信息系统自动抓取生育报销数据，津贴直接发放至女职工，实现了从"人找政策"向"政策找人"转变。"十四五"期间，已为 12.97万人次参保职工发放生育津贴7.3亿元，其中，"即申即享"惠及4.57万人次，基金支出4.11亿元。 12月25日，临沂市召开"十四五"时期临沂市深化医保制度改革情况介绍新闻发布会。记者获悉，"十四五"期间，该市加大生 ...

Group 1: National Healthcare Policy - The National Healthcare Security Administration aims to achieve "no out-of-pocket" expenses for childbirth within the policy scope nationwide by 2026, contingent on the affordability of the healthcare fund [1] - All provinces are required to include suitable childbirth pain relief projects in the fund payment scope and improve the management of insurance payments for assisted reproductive technology projects [1] Group 2: Medical Quality and Safety - The Chongqing Health Commission reported that a preliminary investigation found violations in drug storage practices at a children's hospital, leading to potential disciplinary actions against the involved medical staff [2] - The commission will continue to investigate and enhance medical quality and safety supervision to prevent future violations in medical services [2] Group 3: Pharmaceutical Developments - Junshi Biosciences announced that its clinical trial application for the dual-specific antibody-drug conjugate JS212 for treating advanced solid tumors has been approved by the FDA, marking a significant advancement in drug development [3] - JS212 is expected to be effective against a broader range of tumors and may overcome resistance issues compared to single-target ADC drugs [3] Group 4: Strategic Acquisitions - Zhaoli Pharmaceutical plans to acquire a "multi-trace element injection asset group" from Tibet Future and its two wholly-owned subsidiaries for a total price of 356 million RMB, aimed at optimizing product structure and enhancing competitive strength [4] - The demand for multi-trace element injections is growing in both pediatric nutritional support and adult critical care nutrition sectors, making this acquisition strategically beneficial for Zhaoli Pharmaceutical [4] Group 5: Capital Increase - Shenzhou Cell plans to jointly increase capital by 3 billion RMB in its subsidiary Shenzhou Cell Engineering, with the company contributing 2.6 billion RMB and its controlling shareholder contributing 400 million RMB [5] - Following the capital increase, the registered capital of Shenzhou Cell Engineering will rise to 1.3 billion RMB, improving the subsidiary's financial structure and reducing operational and financial risks [5]